Novavax shares +16.7% to $2.93.
"Notwithstanding the clinical and commercial success (~$1B in 2012), Synagis' indicated use may be narrower than Novavax's vaccine," says Lazard. Synagis is made by MedImmune.
Respiratory syncytial virus is a common, seasonal, and easily spread virus, characterized by runny noses, coughing, sneezing and fever. However, it can lead to severe lung disease in infants.